Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2296647 | 1.00 | APAF1 (0.53) | APAF1SLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL2295948 | 1.00 | APAF1 (0.53) | APAF1SLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL2295951 | 1.00 | APAF1 (0.53) | APAF1SLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL82473 | 1.00 | APAF1 (0.53) | APAF1SLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL2293870 | 1.00 | APAF1 (0.53) | APAF1SLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL14943968 | 0.90 | APAF1 (0.62) | APAF1SLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL10879127 | 0.90 | APAF1 (0.62) | APAF1SLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL10879125 | 0.90 | APAF1 (0.62) | APAF1SLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL15899286 | 0.85 | KDM4E (0.56) | APAF1KDM4EL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3937954 | 0.85 | KDM4E (0.56) | APAF1KDM4EL3MBTL1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-18 | — | — | US | claimed |
| US-8592417-B2 | 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8518939-B2 | 6-pyrimidinyl-pyrimid-4-one derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-27 | — | — | US | disclosed |
| US-8518939-B2 | 6-pyrimidinyl-pyrimid-4-one derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-27 | — | — | US | disclosed |
| US-8518939-B2 | 6-pyrimidinyl-pyrimid-4-one derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-2197877-B1 | 3-METHYL-2- ( (2S) -2- (4- (3-METHYL-1, 2, 4-OXADIAZOL-5-YL) PHENYL) MORPHOLINO) -6- (PYRIMIDIN-4-YL) PYRIMIDIN-4 (3H) -ONE AS TAU PROTEIN KINASE INHIBITOR | SANOFI SA (FR) | 2013-05-15 | — | — | EP | disclosed |
| EP-2197877-B1 | 3-METHYL-2- ( (2S) -2- (4- (3-METHYL-1, 2, 4-OXADIAZOL-5-YL) PHENYL) MORPHOLINO) -6- (PYRIMIDIN-4-YL) PYRIMIDIN-4 (3H) -ONE AS TAU PROTEIN KINASE INHIBITOR | SANOFI SA (FR) | 2013-05-15 | — | — | EP | disclosed |
| EP-2193129-B1 | 6-PYRIMIDINYL-PYRIMID-2-ONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-10-24 | — | — | EP | disclosed |
| EP-2193129-B1 | 6-PYRIMIDINYL-PYRIMID-2-ONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-8288383-B2 | 3-methyl-2- ( (2S) -2- (4- (3-methyl-L, 2, 4-oxadiazol-5-YL) phenyl) morpholino) -6- (pyrim-idin-4-yl) pyrimidin-4 (3H) -one as tau protein kinase inhibitor | SANOFI (FR) | 2012-10-16 | — | — | US | disclosed |
| US-20100113775-A1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113775-A1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113775-A1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20090239864-A1 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI PHARMA CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-2078717-A1 | 6-Pyrimidinyl-pyrimid-2-one derivative | sanofi-aventis (FR) | 2009-07-15 | — | — | EP | disclosed |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2009-05-14 | — | — | US | disclosed |
| WO-2009035159-A1 | 3-METHYL-2- ( (2S) -2- (4- (3-METHYL-L, 2, 4-0XADIAZ0L-5-YL) PHENYL) MORPHOLINO) -6- (PYRIMIDIN-4-YL) PYRIMIDIN-4 (3H) -ONE AS TAU PROTEIN KINASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-19 | — | — | WO | disclosed |
| EP-1789414-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006028290-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MAPT, PSEN1, PSEN2 | APAF1 4120/4885SLC6A2 753/4885SLC6A4 1634/4885 |
| US-20100113775-A1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHIBITORS | MAPT, TTBK1, TTBK2 | APAF1 3044/4885SLC6A2 2731/4885SLC6A4 3869/4885 |
| US-20090239864-A1 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MAPT, TTBK1, PSEN1 | APAF1 2986/4885SLC6A2 2572/4885SLC6A4 3185/4885 |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | APAF1 3130/4885SLC6A2 4107/4885SLC6A4 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.